Yumanity To Reverse Merge With Kineta Two Years After Its Own Public Debut

After its August 2020 reverse merger, neuroscience-focused Yumanity is calling it quits with two transactions: an asset sale to Janssen and a merger with private cancer immunotherapy firm Kineta.

Concept Image For Deals
Yumanity is reverse merging with Kineta, enabling the latter to go public • Source: Alamy

Less than two years after going public via a reverse merger with troubled cystic fibrosis company Proteostasis Therapeutics, Inc., Yumanity Therapeutics, Inc. is winding up its operations by selling off its lead clinical candidate and preclinical neuroscience pipeline to Johnson & Johnson and merging with Kineta, Inc. in a transaction that will confer Yumanity’s NASDAQ listing to the privately held cancer immunotherapy firm.

Upon close of the all-stock transaction announced 6 June, the resulting company will be named Kineta Inc., based in Seattle...

More from Deals

More from Business

Novartis’s Cosentyx Suffers Rare Phase III Fail

 
• By 

Multi-blockbuster falls short in a giant cell arteritis study.

In Brief: BioVersys And Shionogi Align In Non-Tuberculous Mycobacteria R&D

 
• By 

Deal Snapshot: Having recently raised an $89m IPO, BioVersys is partnering on and optioning rights to a preclinical NTM development program with Shionogi.

BerGenBio Plumps For Oncoinvent From Long List Of 50 Suitors

 
• By 

The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.